{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:09:57Z","timestamp":1790172597187,"version":"4.1.0"},"reference-count":200,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"European Union\u2019s Horizon 2020 research and innovation programme","award":["691119 \u2014 EU4HIVCURE \u2014 H2020-MSCA-RISE-2015"],"award-info":[{"award-number":["691119 \u2014 EU4HIVCURE \u2014 H2020-MSCA-RISE-2015"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.bcp.2017.07.001","type":"journal-article","created":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T18:01:41Z","timestamp":1499191301000},"page":"10-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["On the way to find a cure: Purging latent HIV-1 reservoirs"],"prefix":"10.1016","volume":"146","author":[{"given":"Christian","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bouchat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Marban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Van Lint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Le Douce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2017.07.001_b0005","unstructured":"UN\/WHO. AIDS Epidemic Update. http:\/\/www.unaids.org\/en\/, 2016."},{"issue":"11","key":"10.1016\/j.bcp.2017.07.001_b0010","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bcp.2017.07.001_b0015","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team","volume":"337","author":"Hammer","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcp.2017.07.001_b0020","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/QAD.0000000000000243","article-title":"Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy","volume":"28","author":"May","year":"2014","journal-title":"AIDS."},{"issue":"26","key":"10.1016\/j.bcp.2017.07.001_b0025","doi-asserted-by":"crossref","first-page":"15109","DOI":"10.1073\/pnas.96.26.15109","article-title":"HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression","volume":"96","author":"Davey","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2017.07.001_b0030","first-page":"S21","article-title":"Impact of nucleoside reverse transcriptase inhibitors on coronary heart disease","volume":"15","author":"Mallon","year":"2014","journal-title":"Rev. Cardiovasc. Med."},{"issue":"6","key":"10.1016\/j.bcp.2017.07.001_b0035","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/14787210.2016.1184570","article-title":"Protecting bone in long-term HIV positive patients receiving antiretrovirals","volume":"14","author":"McGinty","year":"2016","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.bcp.2017.07.001_b0040","article-title":"Predictors of longitudinal change in bone mineral density in a cohort of HIV-positive and negative subjects","volume":"1","author":"Tinago","year":"2017","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.bcp.2017.07.001_b0045","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/QAD.0b013e32835cb747","article-title":"Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment","volume":"27","author":"Lapadula","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2017.07.001_b0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.antiviral.2015.03.002","article-title":"Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort","volume":"117","author":"Pacheco","year":"2015","journal-title":"Antiviral Res."},{"issue":"18","key":"10.1016\/j.bcp.2017.07.001_b0055","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1097\/QAD.0b013e3283174636","article-title":"The role of HIV in serious diseases other than AIDS","volume":"22","author":"Phillips","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2017.07.001_b0060","unstructured":"M.J. Glesby, Cardiovascular Complications of HIV Infection, Top Antivir. Med. 24(4) 127\u201331."},{"key":"10.1016\/j.bcp.2017.07.001_b0065","unstructured":"C.M. Wyatt, Kidney Disease and HIV Infection. Top Antivir. Med. 25(1) 13\u20136."},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/COH.0000000000000230","article-title":"Residual inflammation and viral reservoirs: alliance against an HIV cure","volume":"11","author":"Massanella","year":"2016","journal-title":"Curr. Opin. HIV AIDS."},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0075","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/QAD.0b013e32835a1156","article-title":"Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy","volume":"27","author":"Masi\u00e1","year":"2013","journal-title":"AIDS."},{"issue":"9939","key":"10.1016\/j.bcp.2017.07.001_b0080","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","article-title":"Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration","volume":"384","author":"Smith","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1742-4690-10-67","article-title":"HIV-1 transcription and latency: an update","volume":"10","author":"Van Lint","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.bcp.2017.07.001_b0090","doi-asserted-by":"crossref","unstructured":"J. Stein, M. Storcksdieck Genannt Bonsmann, H. Streeck, Barriers to HIV Cure, HLA, 88(4) (2016) 155\u2013163.","DOI":"10.1111\/tan.12867"},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0095","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12977-016-0323-4","article-title":"Are T cells the only HIV-1 reservoir?","volume":"13","author":"Kandathil","year":"2016","journal-title":"Retrovirology"},{"issue":"14","key":"10.1016\/j.bcp.2017.07.001_b0100","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199612000-00001","article-title":"Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study","volume":"10","author":"Liuzzi","year":"1996","journal-title":"AIDS."},{"issue":"18","key":"10.1016\/j.bcp.2017.07.001_b0105","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1097\/QAD.0000000000001281","article-title":"Exploring the anatomical HIV reservoirs","volume":"30","author":"Darcis","year":"2016","journal-title":"AIDS."},{"issue":"12","key":"10.1016\/j.bcp.2017.07.001_b0110","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.tim.2015.11.001","article-title":"Adipose tissue: sanctuary for HIV\/SIV persistence and replication","volume":"23","author":"Pallikkuth","year":"2015","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.bcp.2017.07.001_b0115","doi-asserted-by":"crossref","unstructured":"A. Damouche, T. Lazure, V. Avettand-F\u00e8no\u00ebl, N. Huot, N. Dejucq-Rainsford, A.-P. Satie, et al. Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection. Silvestri G, editor. PLoS Pathog. 11(9) (2015) e1005153.","DOI":"10.1371\/journal.ppat.1005153"},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1084\/jem.20121932","article-title":"Follicular helper T cells serve as the major CD4T cell compartment for HIV-1 infection, replication, and production","volume":"210","author":"Perreau","year":"2013","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0125","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.immuni.2007.07.009","article-title":"Germinal-Center Organization and Cellular Dynamics","volume":"27","author":"Allen","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2017.07.001_b0130","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3389\/fimmu.2016.00397","article-title":"Targeting the brain reservoirs: toward an HIV cure","volume":"7","author":"Marban","year":"2016","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S2055-6640(20)30489-1","article-title":"CNS reservoirs for HIV: implications for eradication","volume":"1","author":"Hellmuth","year":"2015","journal-title":"J. Virus Erad."},{"issue":"8","key":"10.1016\/j.bcp.2017.07.001_b0140","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nm.4108","article-title":"International AIDS Society global scientific strategy: towards an HIV cure 2016","volume":"22","author":"Deeks","year":"2016","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bcp.2017.07.001_b0145","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/COH.0000000000000283","article-title":"Strategies to target non-T-cell HIV reservoirs","volume":"11","author":"Sacha","year":"2016","journal-title":"Curr. Opin. HIV AIDS."},{"issue":"6","key":"10.1016\/j.bcp.2017.07.001_b0150","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1517\/14712598.2015.1036736","article-title":"The therapeutic application of CRISPR\/Cas9 technologies for HIV","volume":"15","author":"Saayman","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12977-016-0270-0","article-title":"CRISPR\/Cas9: a double-edged sword when used to combat HIV infection","volume":"13","author":"Liang","year":"2016","journal-title":"Retrovirology"},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0160","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/COH.0000000000000139","article-title":"Application of gene-editing technologies to HIV-1","volume":"10","author":"Drake","year":"2015","journal-title":"Curr. Opin. HIV AIDS."},{"issue":"103","key":"10.1016\/j.bcp.2017.07.001_b0165","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.addr.2016.04.027","article-title":"Stem cell-based therapies for HIV\/AIDS","volume":"1","author":"Pernet","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0170","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/mt.2013.264","article-title":"Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure?","volume":"22","author":"Younan","year":"2014","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2017.07.001_b0175","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/17474086.2016.1183478","article-title":"HIV+ patients and HIV eradication \u2013 allogeneic transplantation","volume":"9","author":"H\u00fctter","year":"2016","journal-title":"Expert. Rev. Hematol."},{"issue":"3","key":"10.1016\/j.bcp.2017.07.001_b0180","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s13365-014-0308-9","article-title":"Genome editing strategies: potential tools for eradicating HIV-1\/AIDS","volume":"21","author":"Khalili","year":"2015","journal-title":"J. Neurovirol."},{"issue":"21","key":"10.1016\/j.bcp.2017.07.001_b0185","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood-2016-01-678144","article-title":"The clinical applications of genome editing in HIV","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcp.2017.07.001_b0190","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/COH.0b013e328344f35e","article-title":"Epidemiology and clinical characteristics of elite controllers","volume":"6","author":"Okulicz","year":"2011","journal-title":"Curr. Opin. HIV AIDS."},{"issue":"3","key":"10.1016\/j.bcp.2017.07.001_b0195","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/COH.0b013e328345a328","article-title":"Elite controllers as a model of functional cure","volume":"6","author":"Autran","year":"2011","journal-title":"Curr. Opin. HIV AIDS."},{"issue":"3","key":"10.1016\/j.bcp.2017.07.001_b0200","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.immuni.2007.08.010","article-title":"Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy","volume":"27","author":"Deeks","year":"2007","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.bcp.2017.07.001_b0205","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nri3478","article-title":"Unravelling the mechanisms of durable control of HIV-1","volume":"13","author":"Walker","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1128\/JVI.01763-08","article-title":"Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy","volume":"83","author":"Hatano","year":"2009","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.bcp.2017.07.001_b0215","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2010-12-327106","article-title":"Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers","volume":"118","author":"S\u00e1ez-Ciri\u00f3n","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2017.07.001_b0220","doi-asserted-by":"crossref","unstructured":"E.H. Graf, A.M. Mexas, J.J. Yu, F. Shaheen, M.K. Liszewski, M. Di Mascio, et al., Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. Emerman M, editor. PLoS Pathog. 7(2) (2011) e1001300.","DOI":"10.1371\/journal.ppat.1001300"},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0225","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tim.2014.11.003","article-title":"Elite control of HIV: is this the right model for a functional cure?","volume":"23","author":"Cockerham","year":"2015","journal-title":"Trends Microbiol."},{"issue":"11","key":"10.1016\/j.bcp.2017.07.001_b0230","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/infdis\/jiu809","article-title":"Hospitalization rates and reasons among HIV Elite Controllers and persons with medically Controlled HIV Infection","volume":"211","author":"Crowell","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.bcp.2017.07.001_b0235","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1089\/aid.2012.0367","article-title":"Rate and predictors of non-AIDS Events in a Cohort of HIV-Infected Patients with a CD4 T Cell Count Above 500 Cells\/mm3","volume":"29","author":"Lucero","year":"2013","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0240","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2055-6640(20)30488-X","article-title":"Clinical outcomes and antiretroviral therapy in \u201celite\u201d controllers: a review of the literature","volume":"1","author":"Crowell","year":"2015","journal-title":"J. Virus Erad."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11904-016-0296-x","article-title":"Post-Treatment Controllers: role in HIV \u201cCure\u201d research","volume":"13","author":"Cockerham","year":"2016","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"6","key":"10.1016\/j.bcp.2017.07.001_b0250","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jamainternmed.2013.2176","article-title":"Immunovirologic control 24months after interruption of antiretroviral therapy initiated close to HIV seroconversion","volume":"173","author":"Hocqueloux","year":"2013","journal-title":"JAMA Intern Med."},{"issue":"16","key":"10.1016\/j.bcp.2017.07.001_b0255","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1001\/archinternmed.2012.2719","article-title":"Immunovirologic control 24months after interruption of antiretroviral therapy initiated close to HIV seroconversion","volume":"172","author":"Lodi","year":"2012","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.bcp.2017.07.001_b0260","doi-asserted-by":"crossref","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","article-title":"Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study","volume":"9","author":"S\u00e1ez-Ciri\u00f3n","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2017.07.001_b0265","doi-asserted-by":"crossref","first-page":"e03821","DOI":"10.7554\/eLife.03821","article-title":"HIV-1 DNA predicts disease progression and post-treatment virological control","volume":"3","author":"Williams","year":"2014","journal-title":"Elife"},{"issue":"7512","key":"10.1016\/j.bcp.2017.07.001_b0270","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nature13594","article-title":"Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys","volume":"512","author":"Whitney","year":"2014","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bcp.2017.07.001_b0275","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/infdis\/jiu297","article-title":"HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment","volume":"210","author":"Luzuriaga","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.bcp.2017.07.001_b0280","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/jac\/dkv084","article-title":"Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission","volume":"70","author":"Ch\u00e9ret","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.bcp.2017.07.001_b0285","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"Hutter","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0290","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11262-005-2503-5","article-title":"The molecular mechanism of human resistance to HIV-1 infection in persistently infected individuals\u2013a review, hypothesis and implications","volume":"31","author":"Becker","year":"2005","journal-title":"Virus Genes"},{"key":"10.1016\/j.bcp.2017.07.001_b0295","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atg.2013.05.004","article-title":"C-C chemokine receptor type five (CCR5): an emerging target for the control of HIV infection","volume":"2","author":"Barmania","year":"2013","journal-title":"Appl. Transl. Genomics."},{"issue":"10","key":"10.1016\/j.bcp.2017.07.001_b0300","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2010-09-309591","article-title":"Evidence for the cure of HIV infection by CCR5\u039432\/\u039432 stem cell transplantation","volume":"117","author":"Allers","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2017.07.001_b0305","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/jac\/dkr599","article-title":"Achieving a cure for HIV infection: do we have reasons to be optimistic?","volume":"67","author":"Le Douce","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.bcp.2017.07.001_b0310","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/M14-1027","article-title":"Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases","volume":"161","author":"Henrich","year":"2014","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.bcp.2017.07.001_b0315","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1084\/jem.185.4.621","article-title":"Change in coreceptor use correlates with disease progression in HIV-1\u2013infected individuals","volume":"185","author":"Connor","year":"1997","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.bcp.2017.07.001_b0320","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1056\/NEJMc1405805","article-title":"Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation","volume":"371","author":"Kordelas","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bcp.2017.07.001_b0325","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrmicro3352","article-title":"Eradicating HIV-1 infection: seeking to clear a persistent pathogen","volume":"12","author":"Archin","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0330","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12981-016-0114-y","article-title":"Stem cell transplantation in strategies for curing HIV\/AIDS","volume":"13","author":"H\u00fctter","year":"2016","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.bcp.2017.07.001_b0335","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coviro.2015.06.007","article-title":"CCR5\u039432 mutation and HIV infection: basis for curative HIV therapy","volume":"14","author":"Allers","year":"2015","journal-title":"Curr. Opin. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0340","doi-asserted-by":"crossref","first-page":"e1004677","DOI":"10.1371\/journal.pcbi.1004677","article-title":"Residual Viremia in Treated HIV+ Individuals","volume":"12","author":"Conway","year":"2016","journal-title":"PLoS Comput. Biol."},{"issue":"17","key":"10.1016\/j.bcp.2017.07.001_b0345","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1073\/pnas.1419162112","article-title":"Post-treatment control of HIV infection","volume":"112","author":"Conway","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2017.07.001_b0350","doi-asserted-by":"crossref","unstructured":"L. Rong, A.S. Perelson, Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on Potent Therapy. Antia R, editor. PLoS Comput Biol. 5(10) (2009) e1000533.","DOI":"10.1371\/journal.pcbi.1000533"},{"key":"10.1016\/j.bcp.2017.07.001_b0355","doi-asserted-by":"crossref","unstructured":"A.L. Hill, D.I.S. Rosenbloom, E. Goldstein, E. Hanhauser, D.R. Kuritzkes, R.F. Siliciano, et al. Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV. Weinberger L, editor. PLOS Pathog. 12(4) (2016) e1005535.","DOI":"10.1371\/journal.ppat.1005535"},{"issue":"37","key":"10.1016\/j.bcp.2017.07.001_b0360","doi-asserted-by":"crossref","first-page":"13475","DOI":"10.1073\/pnas.1406663111","article-title":"Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1","volume":"111","author":"Hill","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2017.07.001_b0365","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1574-6976.2012.00335.x","article-title":"HIV latency: experimental systems and molecular models","volume":"36","author":"Hakre","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0370","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.virol.2010.12.041","article-title":"HIV reservoirs and latency models","volume":"411","author":"Pace","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.bcp.2017.07.001_b0375","doi-asserted-by":"crossref","unstructured":"C.A. Spina, J. Anderson, N.M. Archin, A. Bosque, J. Chan, M. Famiglietti, et al., An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients. Emerman M, editor. PLoS Pathog. 9(12) (2013) e1003834.","DOI":"10.1371\/journal.ppat.1003834"},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0380","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1742-4690-10-90","article-title":"HIV latency and integration site placement in five cell-based models","volume":"10","author":"Sherrill-Mix","year":"2013","journal-title":"Retrovirology"},{"issue":"3","key":"10.1016\/j.bcp.2017.07.001_b0385","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 Cure","volume":"155","author":"Ho","year":"2013","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bcp.2017.07.001_b0390","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cell.2015.02.009","article-title":"A hardwired HIV latency program","volume":"160","author":"Razooky","year":"2015","journal-title":"Cell"},{"issue":"37","key":"10.1016\/j.bcp.2017.07.001_b0395","doi-asserted-by":"crossref","first-page":"13251","DOI":"10.1073\/pnas.1413362111","article-title":"Stochastic variability in HIV affects viral eradication","volume":"111","author":"Rouzine","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0400","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nsmb.3328","article-title":"Position effects influence HIV latency reversal","volume":"24","author":"Chen","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0405","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nsmb.3358","article-title":"Single-virus tracking uncovers the missing link between HIV integration site location and viral gene expression","volume":"24","author":"Ciuffi","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"Suppl. 3","key":"10.1016\/j.bcp.2017.07.001_b0410","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1093\/infdis\/jiw637","article-title":"In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies","volume":"215","author":"Nixon","year":"2017","journal-title":"J Infect Dis."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0415","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/QAD.0000000000001267","article-title":"Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques","volume":"31","author":"Gama","year":"2017","journal-title":"AIDS."},{"key":"10.1016\/j.bcp.2017.07.001_b0420","doi-asserted-by":"crossref","unstructured":"Nath A, Clements JE. Eradication of HIV from the brain: reasons for pause. Vol. 25, AIDS (London, England), 2011, pp. 577\u2013580.","DOI":"10.1097\/QAD.0b013e3283437d2f"},{"key":"10.1016\/j.bcp.2017.07.001_b0425","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.coviro.2016.06.010","article-title":"Humanized mice for HIV and AIDS research","volume":"19","author":"Victor","year":"2016","journal-title":"Curr Opin Virol."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0430","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-016-0268-7","article-title":"In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection","volume":"13","author":"Tsai","year":"2016","journal-title":"Retrovirology"},{"issue":"3","key":"10.1016\/j.bcp.2017.07.001_b0435","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s13365-014-0299-6","article-title":"Humanized mouse models for HIV-1 infection of the CNS","volume":"21","author":"Honeycutt","year":"2015","journal-title":"J. Neurovirol."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0440","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13148-015-0137-6","article-title":"Epigenetic control of HIV-1 post integration latency: implications for therapy","volume":"7","author":"Kumar","year":"2015","journal-title":"Clin. Epigenetics."},{"issue":"25","key":"10.1016\/j.bcp.2017.07.001_b0445","doi-asserted-by":"crossref","first-page":"19434","DOI":"10.1074\/jbc.M110.107607","article-title":"DNA cytosine methylation in the bovine leukemia virus promoter is associated with latency in a lymphoma-derived B-cell line: potential involvement of direct inhibition of cAMP-responsive element (CRE)-binding protein\/CRE modulator\/activation transcription","volume":"285","author":"Pierard","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2017.07.001_b0450","doi-asserted-by":"crossref","first-page":"e1000554","DOI":"10.1371\/journal.ppat.1000554","article-title":"CpG methylation controls reactivation of HIV from latency","volume":"5","author":"Blazkova","year":"2009","journal-title":"PLoS Pathog."},{"issue":"6","key":"10.1016\/j.bcp.2017.07.001_b0455","doi-asserted-by":"crossref","first-page":"e1000495","DOI":"10.1371\/journal.ppat.1000495","article-title":"Epigenetic regulation of HIV-1 latency by cytosine methylation","volume":"5","author":"Kauder","year":"2009","journal-title":"PLoS Pathog."},{"issue":"9","key":"10.1016\/j.bcp.2017.07.001_b0460","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1128\/JVI.00040-12","article-title":"Paucity of HIV DNA Methylation in Latently Infected, Resting CD4+ T Cells from Infected Individuals Receiving Antiretroviral Therapy","volume":"86","author":"Blazkova","year":"2012","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/j.bcp.2017.07.001_b0465","doi-asserted-by":"crossref","first-page":"13081","DOI":"10.1128\/JVI.01741-12","article-title":"Long-term nonprogressor and elite controller patients who control viremia have a higher percentage of methylation in their HIV-1 proviral promoters than aviremic patients receiving highly active antiretroviral therapy","volume":"86","author":"Palacios","year":"2012","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0470","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13148-016-0185-6","article-title":"Development of 5\u2018 LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals","volume":"8","author":"Trejbalov\u00e1","year":"2016","journal-title":"Clin. Epigenetics."},{"issue":"4","key":"10.1016\/j.bcp.2017.07.001_b0475","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1189\/jlb.0409264","article-title":"HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes","volume":"87","author":"Redel","year":"2010","journal-title":"J. Leukoc. Biol."},{"issue":"5","key":"10.1016\/j.bcp.2017.07.001_b0480","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/jcp.24490","article-title":"The many lives of CTIP2: from AIDS to cancer and cardiac hypertrophy","volume":"229","author":"Le Douce","year":"2014","journal-title":"J. Cell. Physiol."},{"issue":"45","key":"10.1016\/j.bcp.2017.07.001_b0485","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1038\/sj.onc.1208904","article-title":"BCL11B functionally associates with the NuRD complex in T lymphocytes to repress targeted promoter","volume":"24","author":"Cismasiu","year":"2005","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.bcp.2017.07.001_b0490","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/MCB.00062-16","article-title":"Protein Kinase C-Mediated Phosphorylation of BCL11B at Serine 2 Negatively Regulates Its Interaction with NuRD Complexes during CD4+T-Cell Activation","volume":"36","author":"Dubuissez","year":"2016","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0495","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/sj.emboj.7601516","article-title":"Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing","volume":"26","author":"Marban","year":"2007","journal-title":"Embo J."},{"issue":"7","key":"10.1016\/j.bcp.2017.07.001_b0500","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/nar\/gki529","article-title":"COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells","volume":"33","author":"Marban","year":"2005","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.bcp.2017.07.001_b0505","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1128\/JVI.77.9.5415-5427.2003","article-title":"Recruitment of Tat to heterochromatin protein HP1 via interaction with CTIP2 inhibits human immunodeficiency virus type 1 replication in microglial cells","volume":"77","author":"Rohr","year":"2003","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.bcp.2017.07.001_b0510","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/nar\/gkr857","article-title":"LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing","volume":"40","author":"Le Douce","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.bcp.2017.07.001_b0515","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1128\/JVI.03333-13","article-title":"Epigenetic regulation of HIV-1 latency in astrocytes","volume":"88","author":"Narasipura","year":"2014","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0520","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.emboj.7601517","article-title":"Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency","volume":"26","author":"du Chene","year":"2007","journal-title":"Embo J."},{"key":"10.1016\/j.bcp.2017.07.001_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2014.02.008","article-title":"Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure","author":"Mbonye","year":"2014","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0530","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1097-2765(01)00314-8","article-title":"NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II","volume":"8","author":"Barboric","year":"2001","journal-title":"Mol. Cell"},{"issue":"6968","key":"10.1016\/j.bcp.2017.07.001_b0535","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nature02171","article-title":"The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes","volume":"426","author":"Ganesh","year":"2003","journal-title":"Nature"},{"issue":"31","key":"10.1016\/j.bcp.2017.07.001_b0540","doi-asserted-by":"crossref","first-page":"12655","DOI":"10.1073\/pnas.1220136110","article-title":"CTIP2 is a negative regulator of P-TEFb","volume":"110","author":"Cherrier","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.bcp.2017.07.001_b0545","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1093\/nar\/gku168","article-title":"HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters","volume":"42","author":"Eilebrecht","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"10.1016\/j.bcp.2017.07.001_b0550","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1128\/JVI.79.7.4479-4491.2005","article-title":"Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation","volume":"79","author":"Vazquez","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2017.07.001_b0555","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2009.193","article-title":"p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1","author":"Cherrier","year":"2009","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0560","doi-asserted-by":"crossref","first-page":"34920","DOI":"10.1038\/srep34920","article-title":"HIC1 controls cellular- and HIV-1-gene transcription via interactions with CTIP2 and HMGA1","volume":"6","author":"Le Douce","year":"2016","journal-title":"Sci Rep."},{"issue":"3","key":"10.1016\/j.bcp.2017.07.001_b0565","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1023\/A:1011091300321","article-title":"OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion","volume":"21","author":"van Praag","year":"2001","journal-title":"J. Clin. Immunol."},{"issue":"11","key":"10.1016\/j.bcp.2017.07.001_b0570","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1097\/00002030-200207260-00004","article-title":"Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)","volume":"16","author":"Stellbrink","year":"2002","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.bcp.2017.07.001_b0575","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/j.1460-2075.1996.tb00449.x","article-title":"Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation","volume":"15","author":"Van Lint","year":"1996","journal-title":"Embo J."},{"issue":"6","key":"10.1016\/j.bcp.2017.07.001_b0580","doi-asserted-by":"crossref","first-page":"e6093","DOI":"10.1371\/journal.pone.0006093","article-title":"Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection","volume":"4","author":"Reuse","year":"2009","journal-title":"PLoS One."},{"issue":"5\u20136","key":"10.1016\/j.bcp.2017.07.001_b0585","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0006-2952(02)01152-8","article-title":"Diversity of acetylation targets and roles in transcriptional regulation: the human immunodeficiency virus type 1 promoter as a model system","volume":"64","author":"Quivy","year":"2002","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0590","doi-asserted-by":"crossref","first-page":"117","DOI":"10.15252\/emmm.201505557","article-title":"Sequential treatment with 5-aza-2\u2019-deoxycytidine and deacetylase inhibitors reactivates HIV-1","volume":"8","author":"Bouchat","year":"2016","journal-title":"EMBO Mol. Med."},{"issue":"12","key":"10.1016\/j.bcp.2017.07.001_b0595","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/QAD.0b013e32835535f5","article-title":"Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients","volume":"26","author":"Bouchat","year":"2012","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0600","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/aid.2014.0199","article-title":"Targeting NF-\u03baB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency","volume":"31","author":"Jiang","year":"2015","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.bcp.2017.07.001_b0605","article-title":"Cyclin-dependent kinases as therapeutic targets for HIV-1 infection","volume":"1\u20139","author":"Rice","year":"2016","journal-title":"Expert. Opin. Ther. Targets."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0610","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1742-4690-3-66","article-title":"Effects of prostratin on Cyclin T1\/P-TEFb function and the gene expression profile in primary resting CD4+ T cells","volume":"3","author":"Sung","year":"2006","journal-title":"Retrovirology"},{"issue":"18","key":"10.1016\/j.bcp.2017.07.001_b0615","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1093\/nar\/gks682","article-title":"PKC phosphorylates HEXIM1 and regulates P-TEFb activity","volume":"40","author":"Fujinaga","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2017.07.001_b0620","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.virol.2014.05.033","article-title":"Reactivation of latent HIV-1 by new semi-synthetic ingenol esters","volume":"462\u2013463","author":"Pandel\u00f3 Jos\u00e9","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.bcp.2017.07.001_b0625","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005063","article-title":"An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to potently reactivate viral gene expression","author":"Darcis","year":"2015","journal-title":"PLoS Pathog."},{"issue":"43","key":"10.1016\/j.bcp.2017.07.001_b0630","doi-asserted-by":"crossref","first-page":"36609","DOI":"10.1074\/jbc.M112.410746","article-title":"Bromodomain and Extra-terminal (BET) Bromodomain Inhibition Activate Transcription via Transient Release of Positive Transcription Elongation Factor b (P-TEFb) from 7SK Small Nuclear Ribonucleoprotein","volume":"287","author":"Bartholomeeusen","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0635","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/nar\/gks976","article-title":"The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation","volume":"41","author":"Li","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0640","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1172\/JCI80565","article-title":"Molecular mechanisms of HIV latency","volume":"126","author":"Cary","year":"2016","journal-title":"J Clin Invest."},{"issue":"4","key":"10.1016\/j.bcp.2017.07.001_b0645","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/COH.0000000000000288","article-title":"Preclinical shock strategies to reactivate latent HIV-1: an update","volume":"11","author":"Darcis","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0650","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/QAD.0000000000001290","article-title":"Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir","volume":"31","author":"Darcis","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2017.07.001_b0655","doi-asserted-by":"crossref","first-page":"16277","DOI":"10.1038\/srep16277","article-title":"CRISPR\/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep."},{"key":"10.1016\/j.bcp.2017.07.001_b0660","article-title":"Open Peer","author":"Cary","year":"2016","journal-title":"Review."},{"issue":"3","key":"10.1016\/j.bcp.2017.07.001_b0665","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/mt.2015.213","article-title":"CRISPR-mediated Activation of Latent HIV-1 Expression","volume":"24","author":"Limsirichai","year":"2016","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2017.07.001_b0670","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/COH.0000000000000278","article-title":"Strategies to target HIV-1 in the central nervous system","volume":"11","author":"Gray","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0675","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40263-012-0018-x","article-title":"CSF penetration by antiretroviral drugs","volume":"27","author":"Eisfeld","year":"2013","journal-title":"CNS Drugs."},{"issue":"6","key":"10.1016\/j.bcp.2017.07.001_b0680","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/QCO.0000000000000014","article-title":"Macrophages: the neglected barrier to eradication","volume":"26","author":"Watters","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.bcp.2017.07.001_b0685","doi-asserted-by":"crossref","first-page":"12442","DOI":"10.1038\/srep12442","article-title":"Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-\u03baB-dependent mechanism","volume":"5","author":"D\u00edaz","year":"2015","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2017.07.001_b0690","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/infdis\/jis412","article-title":"Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy","volume":"206","author":"Blazkova","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bcp.2017.07.001_b0695","series-title":"PLOS Pathog","first-page":"e1005142","article-title":"The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo","author":"S\u00f8gaard","year":"2015"},{"issue":"7408","key":"10.1016\/j.bcp.2017.07.001_b0700","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","volume":"487","author":"Archin","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0705","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.tim.2015.11.003","article-title":"Reversal of Latency as Part of a Cure for HIV-1","volume":"24","author":"Rasmussen","year":"2016","journal-title":"Trends Microbiol."},{"issue":"7","key":"10.1016\/j.bcp.2017.07.001_b0710","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ncomms1100","article-title":"B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection","volume":"1","author":"Huang","year":"2010","journal-title":"Nat Commun"},{"key":"10.1016\/j.bcp.2017.07.001_b0715","doi-asserted-by":"crossref","unstructured":"Pandrea I, Gaufin T, Gautam R, Kristoff J, Mandell D, Montefiori D, et al. Functional Cure of SIVagm Infection in Rhesus Macaques Results in Complete Recovery of CD4+ T Cells and Is Reverted by CD+ Cell Depletion. Desrosiers RC, editor. PLoS Pathog. 2011 Aug;7(8):e1002170.","DOI":"10.1371\/journal.ppat.1002170"},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0720","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nm.3781","article-title":"B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers","volume":"21","author":"Fukazawa","year":"2015","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bcp.2017.07.001_b0725","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.immuni.2016.08.018","article-title":"CD8(+) Lymphocytes are required for maintaining viral suppression in SIV-Infected Macaques Treated with short-term antiretroviral therapy","volume":"45","author":"Cartwright","year":"2016","journal-title":"Immunity"},{"issue":"7348","key":"10.1016\/j.bcp.2017.07.001_b0730","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature10003","article-title":"Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine","volume":"473","author":"Hansen","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0735","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imr.12502","article-title":"B-cell responses to HIV infection","volume":"275","author":"Moir","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bcp.2017.07.001_b0740","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fimmu.2015.00265","article-title":"Can HIV-1-Specific ADCC assist the clearance of reactivated latently infected cells?","volume":"6","author":"Lee","year":"2015","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0745","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI80561","article-title":"Towards HIV-1 remission: potential roles for broadly neutralizing antibodies","volume":"126","author":"Halper-Stromberg","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0750","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/imr.12484","article-title":"Identification and specificity of broadly neutralizing antibodies against HIV","volume":"275","author":"McCoy","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bcp.2017.07.001_b0755","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fimmu.2016.00661","article-title":"Neutralizing Monoclonal Antibodies to Fight HIV-1: on the Threshold of Success","volume":"7","author":"Jaworski","year":"2017","journal-title":"Front Immunol."},{"issue":"36","key":"10.1016\/j.bcp.2017.07.001_b0760","doi-asserted-by":"crossref","first-page":"13151","DOI":"10.1073\/pnas.1414148111","article-title":"Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir","volume":"111","author":"Chun","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.bcp.2017.07.001_b0765","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","article-title":"Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice","volume":"158","author":"Halper-Stromberg","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2017.07.001_b0770","doi-asserted-by":"crossref","unstructured":"Lee WS, Richard J, Lichtfuss M, Smith AB, Park J, Courter JR, et al. Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells. Silvestri G, editor. J Virol. 2016;90(4):2021\u201330.","DOI":"10.1128\/JVI.02717-15"},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0775","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/imr.12506","article-title":"HIV antibodies for treatment of HIV infection","volume":"275","author":"Margolis","year":"2017","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.bcp.2017.07.001_b0780","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ni.3158","article-title":"Antibody responses to envelope glycoproteins in HIV-1 infection","volume":"16","author":"Burton","year":"2015","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2017.07.001_b0785","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/14760584.2016.1129905","article-title":"HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies","volume":"15","author":"Sliepen","year":"2016","journal-title":"Expert. Rev. Vaccines."},{"key":"10.1016\/j.bcp.2017.07.001_b0790","doi-asserted-by":"crossref","unstructured":"Liu J, Ghneim K, Sok D, Bosche WJ, Li Y, Chipriano E, et al. Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science (80). 2016;353(6303):1045\u20139.","DOI":"10.1126\/science.aag0491"},{"key":"10.1016\/j.bcp.2017.07.001_b0795","doi-asserted-by":"crossref","first-page":"10844","DOI":"10.1038\/ncomms10844","article-title":"Elimination of HIV-1-infected cells by broadly neutralizing antibodies","volume":"7","author":"Bruel","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2017.07.001_b0800","doi-asserted-by":"crossref","unstructured":"Sun M, Li Y, Zheng H, Shao Y. Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies. Front Immunol. 2016;7.","DOI":"10.3389\/fimmu.2016.00391"},{"key":"10.1016\/j.bcp.2017.07.001_b0805","doi-asserted-by":"crossref","DOI":"10.1038\/nrd.2016.173","article-title":"Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection","author":"Ferrari","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2017.07.001_b0810","doi-asserted-by":"crossref","unstructured":"Ackerman ME, Mikhailova A, Brown EP, Dowell KG, Walker BD, Bailey-Kellogg C, et al. Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control. Douek DC, editor. PLoS Pathog. 2016;12(1):e1005315.","DOI":"10.1371\/journal.ppat.1005315"},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0815","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11904-016-0310-3","article-title":"NK Cells in HIV Disease","volume":"13","author":"Scully","year":"2016","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"4","key":"10.1016\/j.bcp.2017.07.001_b0820","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/COH.0000000000000286","volume":"11","author":"Kill","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0825","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/imr.12132","article-title":"Exploiting the curative potential of adoptive T-cell therapy for cancer","volume":"257","author":"Hinrichs","year":"2014","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.bcp.2017.07.001_b0830","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.bcp.2017.07.001_b0835","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jcyt.2016.04.007","article-title":"T-cell therapies for HIV: preclinical successes and current clinical strategies","volume":"18","author":"Patel","year":"2016","journal-title":"Cytotherapy."},{"issue":"12","key":"10.1016\/j.bcp.2017.07.001_b0840","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/nm.1779","article-title":"Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor","volume":"14","author":"Varela-Rohena","year":"2008","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bcp.2017.07.001_b0845","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2217\/imt-2016-0121","article-title":"Chimeric antigen receptor engineered stem cells: a novel HIV therapy","volume":"9","author":"Zhen","year":"2017","journal-title":"Immunotherapy"},{"issue":"21","key":"10.1016\/j.bcp.2017.07.001_b0850","doi-asserted-by":"crossref","first-page":"9942","DOI":"10.1128\/JVI.01522-16","article-title":"Adoptive transfer of engineered rhesus simian immunodeficiency virus-specific CD8+ T cells reduces the number of transmitted\/founder viruses established in rhesus macaques","volume":"90","author":"Ayala","year":"2016","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.bcp.2017.07.001_b0855","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0860","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/PPO.0000000000000031","article-title":"CD19-CAR Trials","volume":"20","author":"Ramos","year":"2014","journal-title":"Cancer J."},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b0865","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jiv022","article-title":"Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir","volume":"212","author":"Sung","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"46","key":"10.1016\/j.bcp.2017.07.001_b0870","doi-asserted-by":"crossref","first-page":"33213","DOI":"10.1074\/jbc.M113.509554","article-title":"Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor","volume":"288","author":"Buhrman","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2017.07.001_b0875","doi-asserted-by":"crossref","unstructured":"Butler NS, Theodossis A, Webb AI, Nastovska R, Ramarathinam SH, Dunstone MA, et al. Prevention of Cytotoxic T Cell Escape Using a Heteroclitic Subdominant Viral T Cell Determinant. Buchmeier MJ, editor. PLoS Pathog. 2008;4(10):e1000186.","DOI":"10.1371\/journal.ppat.1000186"},{"issue":"10","key":"10.1016\/j.bcp.2017.07.001_b0880","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMp068087","article-title":"T-cell costimulation\u2013biology, therapeutic potential, and challenges","volume":"355","author":"Sharpe","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bcp.2017.07.001_b0885","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nm.4113","article-title":"PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals","volume":"22","author":"Banga","year":"2016","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bcp.2017.07.001_b0890","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1189\/jlb.4HI0616-255R","article-title":"Frontline science: defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1","volume":"100","author":"Patera","year":"2016","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0895","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12977-015-0144-x","article-title":"Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options","volume":"12","author":"Velu","year":"2015","journal-title":"Retrovirology"},{"issue":"8","key":"10.1016\/j.bcp.2017.07.001_b0900","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/vim.2015.0036","article-title":"Heteroclitic peptides increase proliferation and reduce evidence of human immunodeficiency virus-specific CD8+ T Cell dysfunction","volume":"28","author":"Adegoke","year":"2015","journal-title":"Viral Immunol."},{"key":"10.1016\/j.bcp.2017.07.001_b0905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2015.05.001","article-title":"HIV therapeutic vaccines: moving towards a functional cure","volume":"35","author":"Mylvaganam","year":"2015","journal-title":"Curr. Opin. Immunol."},{"issue":"7534","key":"10.1016\/j.bcp.2017.07.001_b0910","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature14053","article-title":"Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations","volume":"517","author":"Deng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.07.001_b0915","article-title":"CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses","author":"Descours","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2017.07.001_b0920","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/jcbfm.2012.153","article-title":"Immunologic privilege in the central nervous system and the blood-brain barrier","volume":"33","author":"Muldoon","year":"2013","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"10","key":"10.1016\/j.bcp.2017.07.001_b0925","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","article-title":"Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial","volume":"3","author":"Leth","year":"2016","journal-title":"Lancet HIV."},{"key":"10.1016\/j.bcp.2017.07.001_b0930","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.coviro.2016.07.003","article-title":"The sooner the better: innate immunity as a path toward the HIV cure","volume":"19","author":"Tomalka","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.bcp.2017.07.001_b0935","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coviro.2016.02.001","article-title":"Which therapeutic strategy will achieve a cure for HIV-1?","volume":"18","author":"Cillo","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.bcp.2017.07.001_b0940","doi-asserted-by":"crossref","unstructured":"Delagr\u00e8verie HM, Delaugerre C, Lewin SR, Deeks SG, Li JZ. Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. Open forum Infect Dis. 2016;3(4):ofw189.","DOI":"10.1093\/ofid\/ofw189"},{"issue":"8 & 9","key":"10.1016\/j.bcp.2017.07.001_b0945","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/gt.2016.41","article-title":"Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study","volume":"23","author":"Kaminski","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.bcp.2017.07.001_b0950","doi-asserted-by":"crossref","first-page":"29530","DOI":"10.1038\/srep29530","article-title":"Host double strand break repair generates HIV-1 strains resistant to CRISPR\/Cas9","volume":"6","author":"Yoder","year":"2016","journal-title":"Sci .Rep."},{"issue":"3","key":"10.1016\/j.bcp.2017.07.001_b0955","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.celrep.2016.03.042","article-title":"CRISPR\/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape","volume":"15","author":"Wang","year":"2016","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.bcp.2017.07.001_b0960","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/mt.2016.24","article-title":"CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape","volume":"24","author":"Wang","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2017.07.001_b0965","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.addr.2016.02.008","article-title":"Getting into the brain: potential of nanotechnology in the management of NeuroAIDS","volume":"103","author":"Nair","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bcp.2017.07.001_b0970","article-title":"Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound","author":"Poon","year":"2016","journal-title":"Neuropharmacology"},{"issue":"24","key":"10.1016\/j.bcp.2017.07.001_b0975","doi-asserted-by":"crossref","first-page":"14050","DOI":"10.1128\/JVI.01701-14","article-title":"Modeling the timing of antilatency drug administration during HIV treatment","volume":"88","author":"Petravic","year":"2014","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.bcp.2017.07.001_b0980","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cell.2015.02.017","article-title":"An evolutionary role for HIV latency in enhancing viral transmission","volume":"160","author":"Rouzine","year":"2015","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bcp.2017.07.001_b0985","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/14728222.2016.1198777","article-title":"Improving combination antiretroviral therapy by targeting HIV-1 gene transcription","volume":"20","author":"Le Douce","year":"2016","journal-title":"Expert. Opin. Ther. Targets."},{"issue":"4","key":"10.1016\/j.bcp.2017.07.001_b0990","doi-asserted-by":"crossref","first-page":"e00465","DOI":"10.1128\/mBio.00465-15","article-title":"The tat inhibitor didehydro-cortistatin A Prevents HIV-1 reactivation from latency","volume":"6","author":"Mousseau","year":"2015","journal-title":"MBio."},{"key":"10.1016\/j.bcp.2017.07.001_b0995","first-page":"121","article-title":"Targeting HIV transcription: the quest for a functional cure","volume":"389","author":"Mousseau","year":"2015","journal-title":"Curr. Top Microbiol. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2017.07.001_b1000","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1586\/14787210.2016.1122525","article-title":"Didehydro-Cortistatin A: a new player in HIV-therapy?","volume":"14","author":"Mousseau","year":"2016","journal-title":"Expert Rev. Anti Infect. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217304781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217304781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T12:47:18Z","timestamp":1659185238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295217304781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":200,"alternative-id":["S0006295217304781"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2017.07.001","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On the way to find a cure: Purging latent HIV-1 reservoirs","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2017.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}